NEW YORK ( TheStreet) -- CHANGE IN RATINGS:
Align Technology (ALGN) was upgraded at Morgan Stanley from underweight to equal weight. Company should see better consumer trends and easing competition, Morgan Stanley said.
Allot Communications (ALLT) was downgraded at Oppenheimer to perform from outperform. Checks point to slowdown, Oppenheimer said.
Bank of America (BAC) was upgraded at JMP Securities from underperform to market perform. Estimates were also boosted, given higher expected industry sales growth, JMP said.CR Bard (BCR) was downgraded at Morgan Stanley from equal weight to underweight. $91 price target. Company has a premium valuation, but is growing slower than its peers, Morgan Stanley said. Biogen Idec (BIIB) was downgraded at Piper Jaffray from overweight to neutral. Valuation call, based on a $168 price target, Piper Jaffray said. Citigroup (C) was upgraded at JMP Securities from underperform to market perform. Company is leveraged to continued economic growth, JMP said. Citigroup was upgraded at Sterne Agee to buy from neutral. $50 price target. New CEO is a positive and the company remains the cheapest stock in the sector, Sterne Agee said. Clear Channel Outdoor Holdings (CCO) was downgraded at Wedbush to underperform from neutral. $6 price target. Weak 4Q checks, Wedbush said. DR Horton (DHI) was upgraded at Stifel Nicolaus from sell to hold. Valuation call, as the sector has sustainable growth tailwinds, Stifel Nicolaus said. Synageva (GEVA) was downgraded at Piper Jaffray from overweight to neutral. $57 price target. Company lacks near-term catalysts, Piper Jaffray said. Goldman Sachs (GS) was upgraded at JMP Securities from underperform to market perform. Earnings should improve in the coming quarters, JMP Securities said. Health Net (HNT) was upgraded at Deutsche Bank from sell to hold. Valuation call, Deutsche Bank said. JPMorgan Chase was upgraded at JMP Securities from underperform to market perform. Industry should see higher sales in key areas, JMP said. Kronos Worldwide (KRO) was downgraded at Oppenheimer to perform from outperform. Comps will remain negative in the first half, Oppenheimer said. Medtronic (MDT) was upgraded at Mizuho from neutral to buy. $49 price target. Spine business should grow through new products and insurance expansion, Mizuho said.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV